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Abstract: Severe or important blood pressure elevations are associated with the risk of 
cardiovascular disease. However, a signiﬁ  cant proportion of myocardial infarctions and strokes 
occur in subjects with only slight elevations or even with normal blood pressure. Both the 
coexistence of other cardiovascular risk factors, such as diabetes or dyslipidemia, or those recently 
recognized, such as elevations of C-reactive protein or abdominal obesity and metabolic syndrome, 
or the presence of target organ damage, such as microalbuminuria, left ventricular hypertrophy, 
mild renal dysfunction or increased intima-media thickness, all indicate the existence of a high 
cardiovascular risk in mild hypertensives or in subjects with normal or high-normal blood pressure. 
Unfortunately, these high-risk patients are often not recognized and thus under-treated.
The 2003 European Societies of Hypertension and Cardiology guidelines emphasize the 
importance of a complete risk assessment and stratiﬁ  cation in subjects at all blood pressure 
categories. The search for other cardiovascular risk factors and target organ damage should 
be encouraged. Identiﬁ  cation of these high-risk patients may allow an earlier indication for 
antihypertensive treatment and for correction of all cardiovascular risk factors. The objective 
would be to impair the progression or to induce the regression of silent vascular damage before 
a clinical event develops.
Keywords: essential hypertension, target organ damage, cardiovascular risk
The concept of cardiovascular risk stratiﬁ  cation 
and early detection of vascular damage
Coronary heart disease and stroke continue to be the leading causes of death and 
disability among adults from developed countries. Their prevalences are strongly 
related to the effects of many different risk factors, including high blood pressure 
(BP), cigarette smoking, dyslipidemia, and diabetes. Recognition that these cardio-
vascular (CV) risk factors often cluster together has focused attention on the concept 
of total CV risk. Thus, managing of CV risk factors should be viewed as an integrated 
strategy of intervention aimed at correcting as many of the underlying causes of CV 
disease as possible.
As the population becomes older and overweight, such as people from developed 
countries, the number of subjects with hypertension continues to increase. Hypertension 
is the most prevalent cardiovascular risk factor all over the world. Pharmacological 
treatment of hypertension has been shown to prolong life and to prevent or delay 
the development of heart failure and nephrosclerosis and to reduce the incidence of 
stroke (Isles et al 1986). The lower the BP attained the better has been the prognosis 
of the hypertensive population. Even small reductions in BP are associated with large 
reductions in CV risk, especially in hypertensive patients with additional CV risk 
factors such as diabetes (Hansson et al 1998).
However, treated hypertensives have an impaired survival and an increased 
mortality from CV disease compared to non-hypertensive subjects of similar age Vascular Health and Risk Management 2008:4(2) 290
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(Andersson et al 1998). A late start of antihypertensive 
therapy, an inadequate control of BP and/or the type of 
therapy employed, or an incomplete and simultaneous 
coverage of the different simultaneous components of the 
global CV risk, could account for the worse prognosis in 
the hypertensive population. Recently published Guidelines 
(Chobanian et al 2003; European Society of Hypertension 
2003) have recognized the need for a strict BP control in 
every hypertensive patient while stressing the existence of 
compelling indications for the utilisation of certain drugs in 
particular when diabetes mellitus or target organ damage 
are present. In this sense, an early detection of hypertensive 
vascular damage and, consequently, adequate cardiovascular 
risk stratiﬁ  cation appears to be one of the most important 
strategies in order to prevent the development of CV disease 
(De Backer et al 2003). Indeed, the future of hypertension 
would aim at the treatment of the global CV risk of the 
patient, it means that it is necessary to look at the CV disease 
as a continuum, to consider all the CV risk factors present 
in a single patient and, for this, it is mandatory an earlier 
detection of vascular damage, considering that the earlier the 
treatment the better the prognosis of the patient.
Hypertension is a well established risk factor for the 
development of all of the clinical manifestations of athero-
sclerosis and cardiovascular disease. Atherosclerosis is a 
generalized disease of the arterial wall, which may progress 
or regress depending on a plethora of factors (Badimon et al 
1993). This dynamic process is characterized by arterial wall 
remodelling that may go unnoticed for a lifetime, but may 
also present as acute vascular disease and become clinically 
manifest. An early detection of the atherosclerotic disease 
(before clinical manifestations have become evident) has 
received an intense attention in the last years. The presence 
of what are called surrogate markers of disease might be 
used to investigate determinants of atherosclerosis at an early 
stage of the process and can, subsequently, assess modiﬁ  ers 
of atherosclerosis disease progression, such as lifestyle and 
pharmacological interventions. In the future, research should 
be aimed at controlling or reversing subclinical target organ 
damage.
Cardiovascular risk stratiﬁ  cation 
in hypertensive patients: what is 
important?
Elevated BP has been found to be related to the development 
of CV disease in a continuous, graded fashion, with no 
indication of a critical value. Indeed, the risk of CV sequelae 
increases with each increment in BP, even within the 
normal range. In a subgroup of the Framingham Heart Study, 
those people with high-normal BP, deﬁ  ned as systolic BP of 
130–139 mmHg, diastolic BP of 85–89 mmHg, or both, had 
higher CV event rates than those with optimal BP, deﬁ  ned as 
systolic BP of less than 120 mmHg and diastolic BP of less 
than 80 mmHg (Vasan et al 2001). These ﬁ  ndings provide 
further support to the theory that patients with high-normal 
BP need to be identiﬁ  ed and managed differently from 
subjects with normal or optimal BP.
In this sense, and according to the European Guidelines 
for managing high BP, due to the presence of additional risk 
factors (Table 1), target organ damage (Table 2), and associ-
ated clinical conditions (Table 3), patients may be at high risk 
of CV events even when their BP is normal or high-normal 
(systolic BP 120–139 mmHg; diastolic BP: 80–89) (Table 
4). Such high-risk patients, although common in clinical 
practice, are often unrecognized and under-treated. Most 
experts recommend an integrated approach of risk manage-
ment to prevent the complications of raised BP. Accordingly, 
the need to start treatment increases in the presence of other 
CV risk factors or when absolute risk reaches a speciﬁ  ed 
threshold. Risk scores proﬁ  les are based on Framingham 
Study data (Low, Moderate, High or Very High CV risk mean 
probabilities to develop CV disease in the next 10 years of 
 15%, 15%–20%, 20%–30%, and  30% respectively), as 
well as SCORE data ( 4%, 4%–5%, 5%–8%, and  8% for 
low, moderate, high, and very high risk of fatal CV disease, 
respectively).
Recognition of the presence of hypertensive target 
organ damage, such as left ventricular hypertrophy (LVH), 
microalbuminuria (MAB) or increased carotid intima media 
thickness (IMT) is highly important and indicates the neces-
sity of beginning antihypertensive therapy in these hyper-
tensive patients. As mentioned earlier, in the vast majority 
Table 1 Risk factors for cardiovascular disease used for 
stratiﬁ  cation
Levels of systolic and diastolic blood pressure
Men   55 years
Women   65 years
Smoking
Dyslipidemia: total cholesterol   250 mg/dl (6.5 mmol/l), or LDL-
cholesterol   155 mg/dl (4 mmol/l), or HDL-cholesterol   40 mg/dl 
(1.0 mmol/l) in men or  48 mg/dl (1.2 mmol/l) in women
Family history of premature cardiovascular disease ( 55 years in men or 
 65 years in women)
Abdominal obesity: abdominal circumference   102 cm in men or 
 88 cm in women
C-reactive protein   1 mg/dl
From ESH/ESC Guidelines (2003).Vascular Health and Risk Management 2008:4(2) 291
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of hypertensive patients the occurrence of major CV events 
is the result of long-term exposure to multiple risk factors, 
and is usually preceded by the development of asymptomatic 
abnormalities at the vascular and cardiac level (Devereux 
et al 1993). This so-called silent target organ damage phase 
represents an intermediate end-point and, in turn, a strong 
independent predictor of an unfavourable outcome.
On the other hand, when a hypertensive patient has type 2 
diabetes or other 3 or more CV risk factors also represents a 
high risk for CV disease. Optimal CV protection in hyperten-
sion requires take into account not only the severity of the 
BP elevation but also the often associated CV risk factors 
(dyslipidemia, diabetes, obesity, smoking…), or the presence 
of target organ damage (LVH, MAB, IMT…). Recently, 
two new CV risk factors, the elevated C-reactive protein 
(CRP) and the cluster of metabolic abnormalities, known as 
metabolic syndrome (MS) have received a great interest due 
to their close association with CV disease.
What about C-reactive protein 
and the risk of CV disease?
Improvements in risk stratiﬁ  cation by identiﬁ  cation of new 
biomarkers have been extensively investigated in the past 
decade. A substantial number of biomarkers, representing 
various stages of atherosclerotic process and/or impaired 
cardiovascular function have been evaluated in addition to 
traditional risk factors. There is strong evidence that inﬂ  am-
mation plays a key role in the cascade of atherosclerosis, both 
in its development and in its complications due to plaque 
instability and rupture.
Various clinical studies have shown that elevated 
C-reactive protein (CRP) levels in healthy populations 
predict vascular events, such as myocardial infarction and 
stroke (Wilson et al 2006), and that measurements of serum 
levels of CRP using a high sensitivity assay (hsCRP) could 
be a powerful research tool in assessing at-risk populations. 
In fact, elevated serum CRP level has been shown to be a 
stronger predictor of incident CV events in dyslipidemic 
men than LDL-cholesterol, and it has a predictive capac-
ity when added to the Framingham risk score (Ridker et al 
2002), Moreover, hs-CRP is also predictive in subjects with 
metabolic syndrome (Ridker et al 2003). Finally, in appar-
ently healthy men and women, a signiﬁ  cant relationship was 
found between elevation of BP, hsCRP and interleukin-6, and 
the combination of hsCRP and hypertension was additive in 
terms of risk prediction (Blake et al 2003).
On the other hand, there are some data suggesting that 
aspirin, angiotensin converting enzyme inhibitors (ACE), and 
HMG Co-A reductase inhibitors (statins), which all reduces 
vascular event rates, also reduce serum levels of hsCRP, and 
therefore hsCRP may potentially guide therapy.
High-sensitivity CRP is useful in those patients whose 
risk stratiﬁ  cation is unclear, especially in those subjects with 
high normal blood pressure or grade I hypertensives with two 
additional established cardiovascular risk factors. Elevated 
hsCRP may be an indication of pharmacological therapy in 
these patients.
Impact of metabolic syndrome on CV 
disease in hypertensive patients
It has been long recognized that hypertension is often a part of 
a wider constellation of metabolic abnormalities that includes 
abdominal (or visceral) obesity, a characteristic dyslipidemia 
(low HDL-cholesterol and high triglycerides), glucose intol-
erance, and insulin resistance, which are the main features of 
the metabolic syndrome (MS). MS is a relatively common 
condition in patients with hypertension, and its frequency has 
been reported as being around 30%, depending on the clini-
cal characteristics and the criteria used (Cuspidi et al 2004). 
The presence of MS has been shown to confer an increased 
risk of CV events, which may, in part, be attributed to the 
individual risk factors which concur in deﬁ  ning it, and in 
part to a cluster of other, often unmeasured variables such 
Table 3 Associated clinical conditions (clinically evident cardio-
vascular or renal disease)
Cerebrovascular disease: ischemic stroke, cerebral hemorraghe, transient 
ischemic attack
Heart disease: myocardial infarction, angina, coronary revascularization, 
congestive heart failure
Renal disease: diabetic nephropathy, renal impairment (serum creatinine   
1.5 mg/dl (133 µmol/l) in men or  1.4 mg/dl (124 µmol/l) in women
Peripheral vascular disease
Advanced retinopathy: hemorraghes or exudates, papilloedema
From ESH/ESC Guidelines (2003).
Table 2 Indicators of target organ damage
Left ventricular hypertrophy: Electrocardiogram (Sokolow-Lyon   38 mm; 
Cornell   2440 mm*ms). Echocardiogram (left ventricular mass 
index   125 g/m2 in men or  110 g/m2 in women.
Ultrasound evidence of arterial wall thickening (carotid intima-media 
thickness   0.9 mm) or atherosclerotic plaque.
Slight increase in serum creatinine: 1.3–1.5 mg/dl (115–133 µmol/l) in 
men or 1.2–1.4 mg/dl (107–124 µmol/l) in women.
Microalbuminuria: urinary albumin excretion 30–300 mg/24h. 
Albumin-to-creatinine ratio   22 mg/g (2.5 mg/mmol) in men 
or  31 mg/g (3.5 mg/mmol) in women.
From ESH/ESC Guidelines (2003).Vascular Health and Risk Management 2008:4(2) 292
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as a proinﬂ  ammatory state, an impaired ﬁ  brinolysis and 
an increased oxidative stress, which usually go along with 
it (Grundy 1999). Recently, it has been demonstrated that 
the adverse prognostic impact of MS may also be extended 
to hypertensive patients (Schillaci et al 2004). Indeed, in a 
prospective observational study of Italian adult subjects with 
essential hypertension, those patients with this syndrome 
(34% of the whole population) carried an increased risk of 
developing cardiac and cerebrovascular events.
Some recent studies reported an increased prevalence of 
LVH, diastolic dysfunction, early carotid atherosclerosis, 
impaired aortic distensibility, hypertensive retinopathy and 
MAB in hypertensive patients with MS when compared to 
those without it (Mule et al 2006). The increased occurrence 
of these signs of subclinical target organ damage, most of 
which are recognized as signiﬁ  cant independent predictors 
of adverse CV and renal outcomes, may partially explain the 
association of the MS with a higher CV and renal risk.
Implications of microalbuminuria 
in hypertensive patients
The presence of MAB (elevated urinary albumin excretion 
below the proteinuric level, ie, MAB: 30–300 mg/24 h or 
urinary albumin/creatinine ratio  2.5 mg/mmol in men, 
and  3.5 mg/mmol in women) has been long recognized 
as a marker of kidney disease and increased CV risk in both 
types 1 and 2 diabetes mellitus. Further clinical evidence 
documented an association between MAB and other CV risk 
factors, target organ damage and risk of CV disease in the 
general population and in speciﬁ  c clinical contexts including 
essential hypertension. There appears to be a linear relation-
ship between the degree of MAB and CV risk. Evaluation 
of MAB is one of the recommended laboratory tests pro-
posed by the European Society of Hypertension Guidelines 
to assess target organ damage in hypertensive subjects. In 
this hypertensive population, the reported prevalence of 
MAB ranges from about 4% to 46% across different studies 
(Reboldi et al 2005). These differences may be explained 
by the huge intraindividual variability in MAB, age and 
ethnicity, discrepancies in the technique of measurement 
and different deﬁ  nitions of MAB. Increased MAB has been 
associated with subclinical hypertensive organ damage. In 
fact, a higher prevalence of concentric LVH and subclinical 
impairment of LV performance, as well as the presence of 
carotid atherosclerosis have been all reported in patients with 
MAB (Pontremolli et al 2002). These associations might per 
se justify a greater incidence of CV events in hypertensive 
patients with MAB. In a 10-year prospective study of more 
than 2000 patients with hypertension, a urinary albumin/cre-
atinine ratio  1.07 mg/mmol strongly and independently 
predicted ischemic heart disease, more than doubling the 
risk (Jensen et al 2000).
Measurement of MAB is an inexpensive test, widely 
available, suitable for use in clinical practice, which could 
represent a useful approach for risk stratiﬁ  cation and for 
identifying patients at high CV risk.
Implications of left ventricular 
hypertrophy in hypertensive patients
In 1969, the Framingham study already demonstrated that 
once LVH is recognized clinically by electrocardiography, 
it represents a strong predictor for CV disease. Lately, 
several studies have reported that electrocardiographically 
or echocardiographically determined LVH is an independ-
ent risk factor for cardiovascular morbidity and mortality 
in essential hypertension (Casale et al 1986; Koren et al 
1991). Cardiovascular event rates are 2 to 4 fold higher in 
the presence of LVH. In hypertension, LVH is initially a 
useful compensatory process to abnormal loading conditions 
but it is also the ﬁ  rst step toward the development of overt 
clinical disease, such as congestive heart failure, ischemic 
heart disease, cardiac dysrhythmias, and stroke. It has also 
Table 4 Stratiﬁ  cation of risk and prognosis
  Blood pressure (mmHg)
Other RF and  Normal  High-normal  Grade 1  Grade 2  Grade 3
disease history  SBP 120–129 or  SBP 130–139 or  SBP 140–159 or  SBP 160–179 or  SBP   180 or
  DBP 80–84  DBP 85–89  DBP 90–99  DBP 100–109  DBP   110
No other RF  Average risk  Average risk  Low added risk  Moderate added risk  High added risk
1–2 RF  Low added risk  Low added risk  Moderate added risk  Moderate added risk  Very high added risk
3 or more RF or  Moderate added risk  High added risk  High added risk  High added risk  Very high added risk
TOD or Diabetes
ACC  High added risk  Very high added risk  Very high added risk  Very high added risk  Very high added risk
Abbreviations: RF, risk factors; SBP, systolic blood pressure; DBP, diastolic blood pressure; TOD, target organ damage; ACC, associate clinical conditions.
From ESH/ESC Guidelines (2003).Vascular Health and Risk Management 2008:4(2) 293
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been demonstrated that left ventricular geometric patterns 
add prognostic information to both the development of 
cardiovascular disease (Koren et al 1991) and the presence 
of extracardiac target organ damage in essential hyperten-
sion. Indeed, hypertensive patients with concentric LVH 
have more advanced target organ damage, such as renal 
(Shigematsu et al 1998; Pontremolli et al 1999) retinal 
(Pontremolli et al 2002), and silent cerebrovascular (Sierra 
et al 2002) involvement, than those with other patterns of 
left ventricular geometry.
A search for the detection of LVH in electrocardiograms 
must be a part of routine clinical examination to all patients 
with CV disease or at risk of CV events. The systematic pro-
cedure of an echocardiogram depends on each site facilities, 
but it can be especially useful in those patients with high-
normal blood pressure or grades I or II hypertension without 
evidence of other signs of target organ damage. The presence 
of LVH in this group of patients indicates a need for a more 
aggressive management of CV risk factors in order to further 
prevent CV damage.
Implications of increased intima media 
thickness in hypertensive patients
B-mode ultrasound imaging technology has evolved to such 
an extent that the walls of superﬁ  cial arteries, such as carotid 
or femoral arteries, can be imaged noninvasively, in real 
time and at high resolution. Arterial wall thickness can be 
measured as a continuous variable from childhood into old 
age. Large observational studies, such as the Rotterdam study 
(Bots et al 1997), and the ARIC study (ARIC Investigators 
1997), and atherosclerosis regression trials of lipid and BP 
modifying pharmacotherapy have established that increased 
intima-media thickness (IMT) of the carotid and femoral 
arteries, as measured noninvasively by B-mode ultrasound, 
is a valid surrogate marker for the progression of athero-
sclerotic disease (Mancini et al 2004). More compelling is 
evidence showing that carotid atheroma is a predictor of 
vascular events and that is useful for risk stratiﬁ  cation. In the 
ARIC study, a strong and graded relationship was observed 
between coronary heart disease incidence and carotid IMT. 
Hazard ratio comparing extreme mean IMT ( 1 mm) to not 
extreme ( 1 mm) yielded 5.07 for women and 1.85 for men. 
The incidence and relative risk of new CV events correlated 
with measurements of carotid IMT after adjustments for age, 
gender, and traditional risk factors.
In the European Guidelines for the management of 
hypertension, IMT was included as one of the recommended 
procedures to assess target organ damage in hypertensive 
subjects. In this sense, an IMT   0.9 mm is considered as a 
marker of target organ damage in essential hypertension.
Treatment of hypertensive patients 
at risk of developing cardiovascular 
diseases
Hypertension and microalbuminuria
The goals of treatment are regression of MAB and preven-
tion of the progression to persistent clinical albuminuria. 
Treatments that lower MAB are also associated with CV 
protection. First of all, a tight BP control has demonstrated 
to slow the progression of the disease compared to less tight 
BP control (UK Prospective Diabetes Study Group 1998; 
Schrier et al 2002).
Angiotensin receptor blockers (ARBs) are considered 
the ﬁ  rst line treatment in patients with type 2 diabetes and 
nephropathy at different clinical stages. In hypertensive 
patients with type 2 diabetes mellitus and MAB, treatment 
with irbesartan 300 mg daily signiﬁ  cantly decreased the rate 
of progression to overt nephropathy (proteinuria) (Parving 
et al 2001). Similar results were found with valsartan com-
pared to amlodipine (Viberti et al 2002).
Although there is no doubt of the usefulness of ARBs in 
the prevention and treatment of type 2 diabetic nephropathy, 
one important criticism of studies is that the use of ACE 
inhibitors was not allowed in patients enrolled in these clini-
cal trials and there was no direct comparison between ARBs 
and ACE inhibitors. The recently reported DETAIL study 
compared telmisartan vs enalapril in 250 type 2 diabetics with 
microalbuminuria (80%) or proteinuria (20%) and normal 
serum creatinine (Barnett et al 2004). The primary endpoint 
was the change in the glomerular ﬁ  ltration rate. At the end 
of the 5-year observation period there were no differences 
between the two treatment regimens.
Another point of interest is the possible additive effect of 
ARBs and ACE inhibitors on renal protection. The COOP-
ERATE study comparing the combination of losartan and 
trandolapril against monotherapy with either drug in patients 
with non-diabetic nephropathy showed a greater effect of the 
combination on a composite endpoint of doubling the serum 
creatinine and end-stage renal disease (Nakao et al 2003). 
These results suggest the possibility of using combined 
RAS blockade in the protection of hypertensive patients 
with renal disease.
MAB can also be prevented. In the BENEDICT study 
(Ruggenenti et al 2004), trandolapril alone or in combination 
with sustained release verapamil prolonged the time to the Vascular Health and Risk Management 2008:4(2) 294
Sierra and de la Sierra
onset of persistent microalbuminuria compared with placebo 
or verapamil alone in normoalbuminuric type 2 diabetics.
Hypertension and left ventricular 
hypertrophy
LVH and its regression with antihypertensive treatment 
clearly inﬂ  uence the risk of future cardiovascular events 
(Verdecchia et al 1998). Several meta-analyses have exam-
ined the effect of the main antihypertensive drug classes on 
LVH regression, the most recent of which included studies 
with ARBs and concluded that LVH regression with ARBs 
was similar to that observed with ACE inhibitors or calcium 
channel blockers. These three classes of drugs were more 
potent LVH regressors than classic treatment with diuretics 
or betablockers (Klingbeil et al 2003). The comparison of 
losartan versus atenolol in the LIFE trial also showed that 
losartan produced greater LVH regression than atenolol 
(Dahlöf et al 2002). This was demonstrated by measuring 
ECG indexes of LVH (the Sokolow-Lyon and the Cornell 
product) in the whole group of patients, or by measuring left 
ventricular mass index by echocardiography in a selected 
subgroup of patients (Devereux et al 2004).
Hypertension and intima media thickness
Few studies have evaluated the effect of antihypertensive 
agents on IMT progression. The ELSA study was performed 
in 2334 hypertensive patients (aged 45–75 years) who were 
randomized to receive lacidipine or atenolol for 4 years, in 
order to compare the effects of treatments on IMT (Zanchetti 
et al 2002). Results showed a greater efﬁ  cacy of lacidipine 
with respect to atenolol on carotid IMT progression and on 
the development of new atherosclerotic plaques.
A sub-study of the INSIGHT trial also compared the 
effects of long-acting nifedipine versus a diuretic combina-
tion (hydrochlorothiazide + amiloride) on IMT progression in 
439 hypertensive patients aged 55–80 years and one or more 
additional risk factors. In the until-end-of-study population, 
IMT progression rates were different between groups in 
favour of long-acting nifedipine (Simon et al 2001).
Finally, the CAMELOT study was carried out to 
evaluate the effect of antihypertensive agents on CV events 
in patients with coronary artery disease and normal BP 
(defined as diastolic BP  100 mmHg with or without 
treatment). A substudy evaluated the change in percent 
coronary atheroma volume determined by intravascular 
ultrasonography in 274 patients. Amlodipine, enalapril or 
placebo were compared. There was a trend toward less 
progression of atherosclerosis in the amlodipine group versus 
placebo (p = 0.12). However, in the subgroup with baseline 
BP above the mean, signiﬁ  cant reduction in progression was 
observed in the amlodipine group compared with placebo 
(p = 0.02). With respect to baseline, there was progression 
in the placebo group (p   0.001), a trend toward progression 
in the enalapril group (p = 0.08), and a lack of progression 
in the amlodipine group (p = 0.31).
Early detection of patients at high 
risk: early BP reduction?
The VALUE trial compared two active antihypertensive 
treatments (valsartan and amlodipine) in high-risk hyperten-
sives older than 50 years (Julius et al 2004). At the end of 
the study there were no differences in the primary endpoint, 
which occurred in 10.6% of valsartan-treated patients and in 
10.4% of amlodipine-treated patients. Some of the prespeci-
ﬁ  ed secondary endpoints were favourable to amlodipine with 
respect to valsartan, including myocardial infarction and 
stroke, whereas valsartan slightly reduced the development 
of heart failure.
The VALUE trial showed important differences in the BP 
reduction achieved by the two treatment regimens. BP dif-
ferences were especially apparent during the ﬁ  rst part of the 
study (4/2.1 mmHg in the ﬁ  rst month) and maintained at more 
than 1 mmHg during all the follow-up in favor of amlodipine. 
In order to separate the BP dependent and independent 
effects of antihypertensive treatment, the VALUE investi-
gators carried out a special case-control analysis choosing 
more than 5000 pairs of patients matched for age, sex, risk 
and, especially, for systolic BP (Weber et al 2004). Using 
this approach, differences in the cardiovascular endpoint 
that favoured amlodipine in the main analysis disappeared. 
However, the main conclusion of the VALUE trial was that 
early BP reduction was clearly more important than the 
type of treatment used for the prevention of cardiovascular 
disease, at least in high-risk hypertensives.
Newer or classical antihypertensive 
agents?
The issue of which antihypertensive agent should be used 
in ﬁ  rst-line treatment has been controversial for almost two 
decades. However, to reach the target of BP recommended 
in international guidelines, two or more antihypertensive 
agents need to be used in most patients. On the other hand, 
the question if there are differences between the newer anti-
hypertensive agents, such as calcium channel blockers, ACE 
inhibitors, and ARBs compared with classical agents, such 
as diuretics and beta-blockers, remains controversial. It has Vascular Health and Risk Management 2008:4(2) 295
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been recently published the ASCOT-BPLA study (Dahlöf 
et al 2005) which tried to answer this question. This study 
included 19257 hypertensive patients aged 40–79 years with 
at least three other CV risk factors. Patients were randomised 
to receive amlodipine, adding perindopril as required, or 
atenolol, adding bendroﬂ  uthiazide as required. By the end 
of the trial, only 15% and 9% were taking amlodipine and 
atenolol monotherapy, respectively. Interpretation of the 
results show that amlodipine-based regimen prevented more 
major CV events and induced less diabetes than the atenolol-
based regimen, and that these effects might not be entirely 
explained by better control of BP.
On the other hand, the new-onset diabetes that can occur 
with some antihypertensive drugs need to be further investi-
gated. However, there are some evidences supporting the idea 
that calcium channel blockers, ACE inhibitors, and ARBs 
offers a better metabolic proﬁ  le than classical agents. These 
data are particularly important in the treatment of high BP 
in the metabolic syndrome.
Closing remarks
In addition to patients with severe elevation of BP or those 
with previous CV disease, it has become more evident that 
slight elevations of BP, even within the normal range might 
be accompanied by other CV risk factors and especially 
by silent target organ damage, such as microalbuminuria, 
LVH or increased IMT, that are only evident by speciﬁ  c 
search.
Identification of these high-risk patients should be 
encouraged, due to the fact that strict BP control and the 
use of certain types of antihypertensive therapy may help to 
effectively reduce CV mortality and morbidity.
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